• Vol.1 (2020); Issue 3 (June):
    5articles
    Sort by
    Latest
    Open Access
    Review
    Nonalcoholic fatty liver disease and portal hypertension
    Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide and has become the second most common indication for liver transplantation as it may progress to cirrhosis and...
    Marvin Ryou ... Gyorgy Baffy
    Published: June 29, 2020 Explor Med. 2020;1:149-169
    DOI: https://doi.org/10.37349/emed.2020.00011
    This article belongs to the special issue Exploring NAFLD/NASH
    View:880
    Download:19
    Open Access
    Original Article
    Reduction of endoglin receptor impairs mononuclear cell-migration
    Aim: To test if the impairment of mononuclear cell (MNC) migration in patients with hereditary hemorrhagic telangiectasia (HHT) is due to the reduction of the endoglin (ENG) receptor on the cell su...
    Zhenying Han ... Hua Su
    Published: June 29, 2020 Explor Med. 2020;1:136-148
    DOI: https://doi.org/10.37349/emed.2020.00010
    View:750
    Download:17
    Open Access
    Original Article
    Placental OPRM1 DNA methylation and associations with neonatal opioid withdrawal syndrome, a pilot study
    Aim: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neonat...
    Elisha M. Wachman ... Huiping Zhang
    Published: June 29, 2020 Explor Med. 2020;1:124-135
    DOI: https://doi.org/10.37349/emed.2020.00009
    This article belongs to the special issue The Biological Basis of Substance Use Disorders
    View:759
    Download:15
    Times Cited: 0
    Open Access
    Meta-Analysis
    GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
    Aim: Recent randomized controlled trials (RCTs) have tested the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) to specifically treat non-alcoholic fatty liver disease (NAFLD). We ...
    Alessandro Mantovani ... Giovanni Targher
    Published: June 29, 2020 Explor Med. 2020;1:108-123
    DOI: https://doi.org/10.37349/emed.2020.00008
    This article belongs to the special issue Exploring Type 2 Diabetes Mellitus
    View:583
    Download:13
    Open Access
    Review
    Perspectives of nonalcoholic fatty liver disease research: a personal point of view
    Rational government of patient fluxes from primary care to hepatology clinic is a priority of nonalcoholic fatty liver disease (NAFLD) research. Estimating pre-test probability of disease, risk of f...
    Amedeo Lonardo, Stefano Ballestri
    Published: June 29, 2020 Explor Med. 2020;1:85-107
    DOI: https://doi.org/10.37349/emed.2020.00007
    This article belongs to the special issue Exploring NAFLD/NASH
    View:893
    Download:30